Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis

Core Insights - Abbott has initiated the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system aimed at treating symptomatic severe aortic stenosis, a prevalent and serious heart valve disease [1][2] - The investigational TAVI system is designed to enhance heart blood flow, ease of use, and precision, and is intended to complement Abbott's existing Navitor™ TAVI system [1][3] - The development of this TAVI system is a step towards integrating artificial intelligence (AI) into procedural capabilities, aiming to improve treatment outcomes for patients with aortic stenosis [1][3][4] Company Developments - Abbott's new TAVI system is part of a broader strategy to address unmet needs in the TAVI market, leveraging insights from physicians and advancements in technology [3][4] - The first procedures using the investigational system were successfully conducted in Uzbekistan, indicating the company's commitment to expanding its TAVI solutions globally [4] Industry Context - Aortic stenosis is the most common primary valve disease, with its prevalence increasing with age, affecting approximately 9% of individuals over 80 years old [2] - The investigational TAVI system represents a minimally invasive treatment option for patients who may be at risk for open-heart surgery due to age or other health conditions [2]